Broker Name: China Galaxy International Securities (Hong Kong) Co., Limited
Date of Report: March 26, 2026
Excerpt from China Galaxy International Securities (Hong Kong) Co., Limited report.
Report Summary
- CSPC Pharmaceutical’s 2025 revenue and net profit came in below expectations, mainly due to delays in recognizing licensing fee income, with a portion of payments to be recognized in 2026. However, management confirms upfront payments received and guides for positive product revenue growth in 2026.
- Product revenue underperformed across all segments, with notable misses in finished drugs, antibiotics, vitamin C, and functional foods. The company expects improvement, particularly in vitamin C, and maintains cost controls on raw materials.
- CSPC maintains a strong pipeline, including a long-acting peptide drug partnered with AstraZeneca, with multiple clinical trial readouts and potential product launches expected in 2026 and beyond.
- The target price is lowered to HK\$11.47 due to slower-than-expected revenue recovery, but the “Add” rating is reiterated based on CSPC’s robust R&D capabilities and innovative drug pipeline. Valuation is underpinned by DCF for innovative assets and P/E for legacy products.
- The company’s financials show a sharp expected rebound in revenue and profit in 2026, supported by a significant pipeline and licensing deals, but with some volatility and execution risks in the near term.
- Key risks include slower sales recovery, generic competition, and clinical setbacks. Potential catalysts include positive clinical data, new product launches, and higher-than-expected sales from new drugs.
Above is an excerpt from a report by China Galaxy International Securities (Hong Kong) Co., Limited. Clients of China Galaxy International Securities (Hong Kong) Co., Limited can be the first to access the full report from the China Galaxy International Securities website: https://www.chinastock.com.hk
